Revolution Medicines Statistics
Total Valuation
RVMD has a market cap or net worth of $15.40 billion. The enterprise value is $13.88 billion.
Important Dates
The last earnings date was Wednesday, November 5, 2025, after market close.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RVMD has 193.32 million shares outstanding. The number of shares has increased by 15.98% in one year.
| Current Share Class | 193.32M |
| Shares Outstanding | 193.32M |
| Shares Change (YoY) | +15.98% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | 2.37% |
| Owned by Institutions (%) | 93.39% |
| Float | 173.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 9.46 |
| P/TBV Ratio | 10.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.05, with a Debt / Equity ratio of 0.26.
| Current Ratio | 8.05 |
| Quick Ratio | 7.86 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -84.35 |
Financial Efficiency
Return on equity (ROE) is -60.76% and return on invested capital (ROIC) is -35.37%.
| Return on Equity (ROE) | -60.76% |
| Return on Assets (ROA) | -32.29% |
| Return on Invested Capital (ROIC) | -35.37% |
| Return on Capital Employed (ROCE) | -51.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.80M |
| Employee Count | 534 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -753,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +65.06% in the last 52 weeks. The beta is 0.96, so RVMD's price volatility has been similar to the market average.
| Beta (5Y) | 0.96 |
| 52-Week Price Change | +65.06% |
| 50-Day Moving Average | 59.79 |
| 200-Day Moving Average | 43.95 |
| Relative Strength Index (RSI) | 81.54 |
| Average Volume (20 Days) | 2,310,012 |
Short Selling Information
The latest short interest is 17.49 million, so 9.04% of the outstanding shares have been sold short.
| Short Interest | 17.49M |
| Short Previous Month | 18.02M |
| Short % of Shares Out | 9.04% |
| Short % of Float | 10.05% |
| Short Ratio (days to cover) | 7.05 |
Income Statement
| Revenue | n/a |
| Gross Profit | -880.49M |
| Operating Income | -1.04B |
| Pretax Income | -961.73M |
| Net Income | -960.98M |
| EBITDA | -1.03B |
| EBIT | -1.04B |
| Earnings Per Share (EPS) | -$5.19 |
Full Income StatementBalance Sheet
The company has $1.93 billion in cash and $414.97 million in debt, giving a net cash position of $1.52 billion or $7.84 per share.
| Cash & Cash Equivalents | 1.93B |
| Total Debt | 414.97M |
| Net Cash | 1.52B |
| Net Cash Per Share | $7.84 |
| Equity (Book Value) | 1.60B |
| Book Value Per Share | 8.42 |
| Working Capital | 1.73B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$761.79 million and capital expenditures -$15.29 million, giving a free cash flow of -$777.08 million.
| Operating Cash Flow | -761.79M |
| Capital Expenditures | -15.29M |
| Free Cash Flow | -777.08M |
| FCF Per Share | -$4.02 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |